Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). (Q53298150)
Jump to navigation
Jump to search
scientific article published on 11 May 2017
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). |
scientific article published on 11 May 2017 |
Statements
Five-weekly S-1 plus cisplatin therapy combined with trastuzumab therapy in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G). (English)
1 reference
Katsuhiko Nosho
1 reference
Narikazu Boku
1 reference
Ichinosuke Hyodo
1 reference
Yuji Miura
1 reference
Yasutaka Sukawa
1 reference
Shuichi Hironaka
1 reference
Misuzu Mori
1 reference
Kazuhiro Nishikawa
1 reference
Shinya Tokunaga
1 reference
Hiroyuki Okuda
1 reference
Takeshi Sakamoto
1 reference
Keisei Taku
1 reference
Kazuo Nishikawa
1 reference
Toshikazu Moriwaki
1 reference
Yuji Negoro
1 reference
Yutaka Kimura
1 reference
Keita Uchino
1 reference
Katsunori Shinozaki
1 reference
Hiroharu Shinozaki
1 reference
Nobuyuki Musha
1 reference
Hirotsugu Yoshiyama
1 reference
Takashi Tsuda
1 reference
Yoshinori Miyata
1 reference
Naotoshi Sugimoto
1 reference
Tsuyoshi Shirakawa
1 reference
Miki Ito
1 reference
Kimio Yonesaka
1 reference
Kenichi Yoshimura
1 reference
Toshimi Takano
1 reference
11 May 2017
1 reference
21
1 reference
84-95
1 reference
1
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference